Shang Hai Zheng Quan Bao·2026-01-20 18:07Core Viewpoint - The major shareholder of Baolingbao Bio-Pharmaceutical Co., Ltd., Ningbo Baopu Futong Asset Management Center (Limited Partnership), has completed its share reduction plan, selling a total of 11,416,905 shares, which represents approximately 3% of the company's total share capital [2][3]. Group 1: Share Reduction Plan - The shareholder, Baopu Futong, initially held 27,046,297 shares, accounting for 7.10684% of the total share capital, and planned to reduce its holdings by up to 11,417,020 shares within a specified period [2]. - The reduction was executed through both centralized bidding and block trading, with a maximum of 2% (7,611,347 shares) allowed to be sold via block trading and 1% (3,805,673 shares) via centralized bidding within any consecutive 90-day period [2][3]. Group 2: Share Reduction Details - The shares were acquired through a private transfer in December 2016, with the selling price ranging from 11.31 to 11.45 CNY per share for centralized bidding and from 8.64 to 8.66 CNY per share for block trading [3]. - The implementation of the reduction plan was in compliance with relevant laws and regulations, ensuring that it did not affect the company's control structure or governance [4][5].